SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 11,341 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 11,341 shares of SiBone stock in a transaction on Monday, November 17th. The shares were sold at an average price of $17.43, for a total value of $197,673.63. Following the completion of the sale, the chief executive officer directly owned 408,363 shares of the company’s stock, valued at $7,117,767.09. This trade represents a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Laura Francis also recently made the following trade(s):

• On Tuesday, November 18th, Laura Francis sold 5,411 shares of SiBone stock. The shares were sold at an average price of $17.70, for a total value of $95,774.70.
• On Tuesday, November 11th, Laura Francis sold 5,411 shares of SiBone stock. The shares were sold at an average price of $17.06, for a total value of $92,311.66.

SiBone Trading Up 2.1%

SIBN stock traded up $0.39 during midday trading on Thursday, reaching $18.99. The stock had a trading volume of 25,139 shares, compared to its average volume of 440,884. The firm has a market cap of $823.76 million, a price-to-earnings ratio of -36.99 and a beta of 0.81. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $15.46 and a two-hundred day simple moving average of $16.74.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company had revenue of $48.66 million for the quarter, compared to analyst estimates of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. SiBone has set its FY 2025 guidance at EPS. As a group, research analysts expect that SiBone will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Cantor Fitzgerald set a $25.00 price target on SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Truist Financial reduced their price target on shares of SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Finally, Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Institutional Trading of SiBone

Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its position in SiBone by 55.0% during the first quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock worth $8,861,000 after buying an additional 224,190 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of SiBone by 3.3% during the 1st quarter. Allianz Asset Management GmbH now owns 133,899 shares of the company’s stock worth $1,879,000 after acquiring an additional 4,288 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in SiBone in the 1st quarter valued at $162,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in SiBone during the first quarter worth $683,000. Finally, Legato Capital Management LLC increased its holdings in shares of SiBone by 58.4% in the first quarter. Legato Capital Management LLC now owns 99,356 shares of the company’s stock valued at $1,394,000 after purchasing an additional 36,649 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.